BioSpace News Archive

GE HealthCare, is announcing that its Vice President and Chief Financial Officer, Jay Saccaro, will be presenting at the following upcoming investor conferences.

Health and wellness advertising agency AbelsonTaylor Group has received two prestigious WorkLife Awards – Best Onboarding Process, recognizing AT Group’s innovative program that seamlessly integrates new hires into the agency; and Best Wellness Program, recognizing the agency’s comprehensive employee wellness initiative which prioritizes staff’s health and well-being.

NurExone Biologic Inc., a biopharmaceutical company, announced the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

KalVista Pharmaceuticals, Inc. announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering.

Establishment Labs Holdings Inc. plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

TheracosBio today announced that it is extending its collaboration with the Mark Cuban Cost Plus Drug Company.

Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the treatment of canine osteoarthritis (OA), a complex chronic disease that affects dogs’ mobility and overall quality of life.

Standard BioTools Inc. today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the market.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug Mytesi to Direct Relief, a Santa Barbara, California-based humanitarian aid organization.